Efficacy of Dendritic Cell Infusion in Advanced Hepatocellular Carcinoma.

L Di,J Ren,G Song,J Yu

DOI: https://doi.org/10.1200/jco.2005.23.16_suppl.4168

IF: 45.3

2005-01-01

Journal of Clinical Oncology

Abstract:4168 Background: Some studies demonstrated that dentritic cell immunotherapy is positive effective therapy in melanoma and prostate cancer. We conducted a pilot study to evaluate the effect of dendritic cell infusion applying in advanced hepatocellular carcinoma. Methods: The 21 patients with hepatocellular carcinoma received chemotherapy and G-CSF used to mobilize peripheral blood hematopoietic stem cell. CD34+ stem cell were induced to differentiate into dendritic cell by cytokines IL-4, GM-CSF, and TNF-a. After cultured for 7 days, dendritic cell were infused into patient’s vein or directly injected into tumors tissue once a week over a 3 week. The response rate, Karnofsky score, AFP and HBV virus copy were checked before and after infusion or injection. Results: The response rate including SD rate is 76%, the tumor shrink demonstrate in 2 patients. Karnofsky score increases in 15 patients. Both the AFP and HBV virus copies decreased, a significant reduction (t=0.014) in AFP serum lever was found. No severe side-effects were found except for diarrhea in 1 patient, fever in 3 patients and liver pain in 2 patients after directly injection into tumor. Conclusions: Dendritc cell immunotherapy is of promising to treat advanced hepatocellular carcinoma without severe side effect. In order to get stronger immune response, loading tumor specialized antigen is crucial. No significant financial relationships to disclose.